|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): September 4, 2018
|
CURE PHARMACEUTICAL HOLDING CORP. |
|
(Exact name of small business issuer as specified in its charter) |
1620 Beacon Place, Oxnard, California 93033
(Address of principal executive offices)
(805) 824-0410
(Issuer's telephone number)
|
Nevada |
|
000-55908 |
|
37-1765151 |
|
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
1620 Beacon Place, Oxnard, California |
|
93033 |
|
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code (805) 824-0410
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x
|
|
|
|
Item 1.01 Entry into a Material Definitive Agreement
On September 4, 2018, Cure Pharmaceutical Holding Corp., through its subsidiary, Cure Pharmaceutical Corp. (together, the “ Company ”) entered into its first multi-year licensing agreement (the “ Licensing Agreement ”) with Canopy Growth Corporation, a company that engages in the production and sale of medical cannabis (“ Canopy ”). Under the terms of the Licensing Agreement, Canopy will have an exclusive license to certain of the Company’s intellectual property rights, including the Company’s patented, multi-layer oral thin film (OTF), CUREfilm™ technology for use with cannabis extracts and biosynthetic cannabinoids (“ Products ”) and the Company’s trademarks in markets around the world where it is legal for Canopy to sell the Products, excluding Asia. The Company will retain the right to manufacture synthetic cannabinoids for pharmaceutical applications.
Canopy will manufacture CUREfilms that deliver cannabis extracts, expanding the commercialization and monetization of the CUREfilm technology. The parties will collaborate on new products and uses for the products.
Canopy shall pay the Company approximately $250,000 for costs associated with a feasibility study and technology transfer as well as certain milestone payments and royalties on product sales by Canopy with minimum royalties starting in 2020.
Item 9.01 Financial Statements & Exhibits
(d) Exhibits
|
Exhibit Number |
|
Description |
|
|
|
2 |
|
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
|
CURE PHARMACEUTICAL HOLDING CORP. |
|||
|
|
|||
|
Date: September 5, 2018 |
By: |
/s/ Rob Davidson |
|
|
Name: |
Rob Davidson |
|
|
|
Title: |
Chief Executive Officer |
||
|
3 |
EXHIBIT 99.1
Media Inquiries:
Ashley Ray
(310) 824 – 9000
aray@olmsteadwilliams.com
CURE Pharmaceutical Expands Distribution of
CUREfilm Technology with First Licensing Agreement
CURE grants cannabis leader rights to its proprietary drug delivery technology in markets around the world
LOS ANGELES – September 5, 2018 - CURE Pharmaceutical (OTC: CURR), (“CURE”), an innovative drug delivery and development company, today announced that it entered into a multi-year licensing agreement for the first time with a leading international cannabis company. Under the terms of the agreement, the cannabis company will have an exclusive license to CURE’s patented, multi-layer oral thin film (OTF), CUREfilm™ technology for use with cannabis extracts and biosynthetic cannabinoids in markets around the world. The parties will collaborate on new products and indications.
“Whole plant extracted, biosynthesized and synthetic cannabinoids all hold therapeutic promise for given indications and intended uses,” said Rob Davidson, CEO and Chairman of CURE Pharmaceutical. “At CURE, we focus on synthetic cannabinoids for CUREfilm products, but with our new licensing business model, we will expand the impact and applications of our technology to these other promising approaches by partnering with an industry leader in this market.”
CURE will enable the manufacturing of CUREfilms that deliver cannabis extracts, expanding the commercialization and monetization of CUREfilm technology. CURE retains the right to manufacture synthetic cannabinoids for pharmaceutical applications.
The CUREfilm license gives the cannabis company a dosage form that is ideal for the delivery of cannabinoids. It offers increased bioavailability, ease and precision of dosing and greater palatability. Cannabinoids are chemical compounds found in plants, such as cannabis (phytocannabinoids), synthesized by cells of the human body (endocannabinoids) or synthesized in a laboratory (biosynthetic cannabinoids) that interact with the body’s endocannabinoid system. The endocannabinoid system is recognized as an important modulatory system in the function of the brain, endocrine and immune tissues.
About CURE Pharmaceutical
CURE Pharmaceutical is a vertically integrated drug delivery and development company committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has a full-service cGMP manufacturing facility and is a pioneering developer and manufacturer of a patented and proprietary delivery system (CUREfilm™), one of the most advanced oral thin film on the market today. CURE is developing an array of products in cutting-edge delivery platforms and partners with biotech and pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada, Israel and Germany, among other markets. The company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced.
For more information about CURE Pharmaceutical, please visit its website at www.curepharmaceutical.com.
|
1 |
|
|
|
Media Inquiries: Ashley Ray (310) 824 – 9000 aray@olmsteadwilliams.com |
Forward-looking Statement
This press release contains forward-looking statements, which are subject to risks and uncertainties. All statements, other than statements of fact, including those statements with respect to the consummation of the asset acquisition or the benefits to be derived from the acquisition if consummated, are forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future events or performance. Whether or not any such forward looking statements are in fact achieved will depend upon future events, some of which are not within the control of CURE. Accordingly, actual results may vary from the projected results and such variations may be material. We undertake no obligation to publicly update or revise any forward-looking statements.
Additional information concerning the licensing agreement can be found in the Company’s Form 8-K filed with the Securities and Exchange Commission on September 5, 2018.
CURE Public Relations Contact:
Ashley Ray
Olmstead Williams Communication
aray@olmsteadwilliams.com
P. 310-824-9000
|
2 |